Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
|ClinicalTrials.gov Identifier: NCT00112710|
Recruitment Status : Unknown
Verified May 2007 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : June 3, 2005
Last Update Posted : August 26, 2013
University Hospital Birmingham
Information provided by:
National Cancer Institute (NCI)
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Primary Completion Date :||No date given|
|Study Completion Date :||No date given|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Ferry D, Billingham L, Jarrett H, Dunlop D, Woll PJ, Nicolson M, Shah R, Thompson J, Spicer J, Muthukumar D, Skailes G, Leonard P, Chetiyawardana AD, Wells P, Lewanski C, Crosse B, Hill M, Gaunt P, O'Byrne K. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. Eur J Cancer. 2017 Sep;83:302-312. doi: 10.1016/j.ejca.2017.05.037. Epub 2017 Aug 4.